Immunic, Inc. (IMUX) Bundle
Un Overview de Immunic, Inc. (Imux)
Resumen general de Immunic, Inc.
Immunic, Inc. (NASDAQ: IMUX) is a clinical-stage biopharmaceutical company founded in 2016, focused on developing novel therapies for serious chronic inflammatory and autoimmune diseases. The company’s lead product candidates include vidofludimus calcium (IMU-838), which is in Phase 3 and Phase 2 clinical development for patients with relapsing and progressive multiple sclerosis (MS), and IMU-856, aimed at regenerative bowel therapy.
As of 2024, Immunic has not generated any revenue from product sales and continues to operate at a loss, with an accumulated deficit of approximately $486.2 million as of September 30, 2024. The company has raised over $430.9 million through various financing rounds since its inception .
| Año | Evento |
|---|---|
| 2016 | Fundado |
| 2024 | Déficit acumulado de $ 486.2 millones |
| 2024 | Cash and cash equivalents of approximately $59.1 million |
| 2024 | Lead product candidates in clinical trials for MS and gastrointestinal diseases |
Desempeño financiero de la empresa en los últimos informes financieros
In the latest financial reporting period, Immunic reported a net loss of $75.332 million for the nine months ended September 30, 2024, compared to a loss of $72.040 million for the same period in 2023. The operating expenses decreased slightly to $72.421 million from $75.842 million año tras año. Research and development expenses were $58.429 million, while general and administrative expenses totaled $13.992 million.
In terms of cash flow, Immunic generated $74.464 million from financing activities during the nine months ended September 30, 2024, primarily from a significant financing round that raised $80 million in January 2024. The first tranche of this financing closed on January 8, 2024, at a price of $1.43 per share.
| Métrica financiera | P3 2024 | P3 2023 |
|---|---|---|
| Pérdida neta | $ 24.368 millones | $22.769 million |
| Pérdida por acción | $0.24 | $0.51 |
| Equivalentes de efectivo y efectivo | $ 59.1 millones | $46.674 million |
| Gastos operativos | $ 72.421 millones | $75.842 million |
Immunic as a Leader in the Industry
Immunic, Inc. stands out as a leader in the biopharmaceutical industry focused on inflammatory and autoimmune diseases. The company is advancing its pipeline with innovative therapeutic candidates that directly address unmet medical needs. Its strategic initiatives include executing ongoing clinical trials and preparing for potential commercialization of its products.
As the company continues to progress with its clinical programs, investors and stakeholders are encouraged to explore the details of Immunic's innovative approaches and their implications for the future of chronic disease treatment.
Mission Statement of Immunic, Inc. (IMUX)
Mission Statement of Immunic, Inc. (IMUX)
Immunic, Inc. is a biotechnology company focused on developing oral therapies aimed at treating chronic inflammatory and autoimmune diseases. The company's mission statement emphasizes its commitment to delivering innovative and effective treatment options to improve patient outcomes.
The significance of the mission statement lies in its role as a guiding beacon for the company's long-term goals, fostering a culture of excellence and integrity in its operations.
Componente central 1: Innovación
Immunic is dedicated to innovation in the field of immunology. The company aims to create unique oral therapies that directly address the unmet needs of patients suffering from serious chronic conditions. For instance, the development of vidofludimus calcium (IMU-838) is currently in Phase 3 and Phase 2 trials for relapsing and progressive multiple sclerosis, respectively. This program has shown promising therapeutic activity in previous trials, highlighting Immunic's focus on advancing treatment modalities that can lead to better health outcomes.
Componente Core 2: Calidad
Quality is central to Immunic's mission. La compañía se compromete a realizar una investigación y un desarrollo exhaustivos para garantizar que sus productos cumplan con los rigurosos estándares de seguridad y eficacia. For example, in the nine months ended September 30, 2024, Immunic reported total operating expenses of $ 72.4 millones, primarily driven by research and development efforts. This substantial investment underscores the company's dedication to delivering high-quality therapeutic options to patients.
Componente del núcleo 3: enfoque centrado en el paciente
Immunic's mission emphasizes a patient-centric approach, focusing on the needs and experiences of patients throughout the development process. La compañía busca activamente interactuar con pacientes y partes interesadas para reunir ideas que informen sus programas de desarrollo clínico. Al 30 de septiembre de 2024, Immunic tenía un déficit acumulado de aproximadamente $ 486.2 millones, reflecting significant investment in its pipeline aimed at addressing patient needs in chronic inflammatory and autoimmune diseases.
| Métrica financiera | Valor (2024) |
|---|---|
| Déficit acumulado | $ 486.2 millones |
| Gastos operativos totales | $ 72.4 millones |
| Equivalentes de efectivo y efectivo | $ 59.1 millones |
| Pérdida neta (9 meses) | $ 75.3 millones |
| Gastos de investigación y desarrollo | $ 58.4 millones |
El compromiso de Immunic con la innovación, la calidad y un enfoque centrado en el paciente se refleja en sus iniciativas estratégicas y ensayos clínicos en curso. La compañía continúa priorizando el desarrollo de terapias que pueden mejorar significativamente la calidad de vida de los pacientes con afecciones crónicas.
Declaración de visión de Immunic, Inc. (IMUX)
Declaración de visión Overview
La declaración de visión de Immunic, Inc. (IMUX) refleja su compromiso de avanzar en terapias innovadoras para pacientes que padecen enfermedades autoinmunes. The company aims to be a leader in the biopharmaceutical industry through its strategic focus on the development of its product candidates, particularly vidofludimus calcium (IMU-838), IMU-856, and IMU-381.
Compromiso con terapias innovadoras
A partir de 2024, Immunic se centra en maximizar el potencial de sus programas de desarrollo a través de ensayos clínicos e iniciativas estratégicas. The company is executing its Phase 3 ENSURE and Phase 2 CALLIPER clinical trial programs of vidofludimus calcium in relapsing multiple sclerosis (RMS) and progressive multiple sclerosis (PMS), respectively. Se espera que la liberación anticipada de datos de la línea superior del ensayo clínico de fase 2B de Vidofludimus calcio sea alrededor de abril de 2025.
Financial Strategy to Support Vision
Immunic's financial strategy is designed to support its vision of becoming a leader in autoimmune disease treatment. In January 2024, the company entered into a Securities Purchase Agreement with accredited investors, securing gross proceeds of approximately $80 million from the first tranche of a private placement. The second tranche, contingent on specific conditions, could yield an additional $80 million.
| Tramo | Bruto | Precio por acción | Conditions for Next Tranche |
|---|---|---|---|
| Primer tramo | $ 80 millones | $1.43 | N / A |
| Segundo tramo | $ 80 millones | $1.716 | Release of topline data, $8.00 10-day VWAP, $100 million trading volume |
| Tercer tramo | Up to $80 million | Same as Second Tranche | Same conditions as Second Tranche |
Enfoque de investigación y desarrollo
Immunic no ha generado ningún ingreso de las ventas de productos y ha incurrido en pérdidas operativas significativas desde su inicio. Al 30 de septiembre de 2024, el déficit acumulado era de aproximadamente $ 486.2 millones. The company continues to prioritize its research and development efforts, with total operating expenses for the nine months ended September 30, 2024, amounting to $72.4 million.
Visión a largo plazo para el crecimiento
La visión a largo plazo de Immunic es establecer una cartera robusta de terapias que aborden las necesidades médicas no satisfechas en las enfermedades autoinmunes. Esta visión está respaldada por ensayos clínicos en curso, colaboraciones estratégicas y un compromiso con la innovación. La compañía tiene planes de continuar su investigación preclínica y explorar indicaciones adicionales para el desarrollo futuro.
Valores centrales de Immunic, Inc. (IMUX)
Integridad
El valor central de Integridad at Immunic, Inc. emphasizes ethical conduct and transparency in all operations. This commitment is critical as it fosters trust among stakeholders, including investors, employees, and patients.
In 2024, Immunic has implemented rigorous compliance programs and ethical guidelines that govern its research and clinical trials. For instance, the company adheres to strict regulatory standards set by the FDA and EMA, ensuring that all clinical trials are conducted ethically and transparently.
Furthermore, Immunic has been proactive in its communications regarding trial outcomes and operational changes. This is evidenced by their updates on the Phase 2b clinical trial of vidofludimus calcium, where the company has committed to releasing topline data expected in April 2025.
Innovación
Innovación is at the heart of Immunic's mission, driving the development of new treatments for chronic inflammatory and autoimmune diseases. La compañía se enfoca en crear terapias novedosas que aborden las necesidades médicas no satisfechas.
As of 2024, Immunic is advancing multiple clinical trials, including the ongoing Phase 3 ENSURE trial and the Phase 2 CALLIPER trial for vidofludimus calcium. The company has invested approximately $356.5 million in research and development since its inception. This substantial investment underscores its commitment to developing innovative solutions for patients.
Colaboración
Immunic promotes Colaboración as a fundamental value, recognizing that partnerships enhance its research capabilities and clinical development efforts. The company actively seeks collaborations with academic institutions and industry partners to leverage expertise and resources.
In 2024, Immunic has entered into several strategic collaborations to facilitate the development of its product candidates. For instance, the January 2024 Financing involved partnerships with various accredited investors, raising a total of $80 million. This funding is intended to support the ongoing clinical development of their lead programs, demonstrating the power of collaborative efforts in advancing healthcare solutions.
Responsabilidad
Responsabilidad is a core value that Immunic embraces to ensure responsible management of its resources and commitments. This value is crucial in maintaining the trust of investors and stakeholders.
As of September 30, 2024, Immunic reported an accumulated deficit of approximately $486.2 million. La compañía reconoce sus desafíos financieros y está comprometida con informes transparentes y estrategias efectivas de gestión financiera. Las actualizaciones periódicas sobre el desempeño financiero y los hitos operativos reflejan la responsabilidad de Immunic ante sus partes interesadas.
Centricción en el paciente
El valor de Centricción en el paciente Impulsa el enfoque de Immunic en el desarrollo de terapias que mejoren significativamente los resultados del paciente. La compañía prioriza las necesidades y experiencias de los pacientes a lo largo de sus procesos de investigación y desarrollo.
En sus ensayos clínicos, Immunic busca activamente la retroalimentación del paciente para refinar sus enfoques y garantizar que las terapias desarrolladas satisfagan las necesidades de los afectados por afecciones crónicas. Los ensayos de fase 2 en curso de Vidofludimus calcio tienen como objetivo abordar las necesidades terapéuticas específicas de pacientes con esclerosis múltiple recurrente y progresiva.
| Valor central | Descripción | 2024 iniciativas |
|---|---|---|
| Integridad | Compromiso con la conducta ética y la transparencia. | Strict adherence to regulatory standards; proactive communication about trial data. |
| Innovación | Concéntrese en desarrollar terapias novedosas para necesidades médicas no satisfechas. | Inversión de $ 356.5 millones en I + D; ensayos clínicos en curso. |
| Colaboración | Mejora de la investigación a través de asociaciones. | $ 80 millones recaudados a través de colaboraciones estratégicas en enero de 2024. |
| Responsabilidad | Gestión responsable de recursos y compromisos. | Actualizaciones regulares sobre el desempeño financiero; Transparencia en los informes. |
| Centricción en el paciente | Priorizar las necesidades y experiencias de los pacientes. | Incorporar la retroalimentación del paciente en ensayos clínicos; centrándose en los resultados del paciente. |
Immunic, Inc. (IMUX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Immunic, Inc. (IMUX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Immunic, Inc. (IMUX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Immunic, Inc. (IMUX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.